Inhibition of hepatic metastasis in mice treated with cell-binding domain of human fibronectin and angiogenesis inhibitor TNP-470.

BACKGROUND: To prevent tumor metastasis, we administered the cell-binding domain of fibronectin, in combination with the angiogenesis inhibitor TNP-470, to mice with hepatic metastasis. We then assessed the prevention of tumor metastasis resulting from the inhibition of adhesive interactions and the inhibition of angiogenesis. METHODS: A hepatic metastasis model was created by injecting 1 x 10(3) colon 26/TC-1 cells into the anterior mesenteric vein of CDF1 mice. The cell-binding domain obtained from fibronectin included the Arg-Gly-Asp (RGD) sequence. A fibronectin-binding domain (FND)-treated group, an FND plus TNP-470 group, and a control group were established. The animals were killed 4 weeks after the injections of the treatment agents had been completed and the number of metastatic liver nodules was counted. In a simultaneous experiment with the same design, the mice were not killed at 4 weeks, and their survival was observed. RESULTS: The mean number of nodules in the FND plus TNP-470 group was significantly lower than that in the control group (P = 0.019337). The inhibition rate was 51% in the FND group, 60% in the FND 10 micrograms plus TNP-470 10 mg/kg group, and 64% in the FND 10 micrograms plus TNP-470 100 mg/kg group compared with the control group. Mice from the FND group that were not killed died after 6-8 weeks, but mice from the FND plus TNP-470 group died after 8-12 weeks. CONCLUSION: The cell-binding domain of fibronectin may, potentially, be an effective form of antiadhesive therapy that competes with native adhesion molecules and blocks adhesion during the metastatic process. When the cell-binding domain of fibronectin is combined with TNP-470 to inhibit angiogenesis, more effective inhibition of metastatic tumor growth and prolongation of survival can be achieved than after treatment with the cell-binding domain alone.

Mannan and D-arabinitol concentrations in serum from a patient with Candida albicans endocarditis.

In an attempt to clarify the comparative values of serological and microbiological examinations for the early diagnosis of systemic candidiasis, antibodies against Candida albicans, serum mannan, and the D-arabinitol creatinine ratio were investigated in a patient with aortic valve endocarditis associated with carcinoma of the bile duct. Candida precipitins and the antibody titer against Candida cell wall mannan were examined by an immunodiffusion technique and hemagglutination test, respectively. Serum mannan was tested by enzyme-linked immunosorbent assay (ELISA) using the biotin-streptavidin procedure. The upper limit of negativity of the assay was determined by adding 0.06 to the absorbance of pooled serum from healthy laboratory workers. This value was about 0.8 ng/ml with ELISA. The D-arabinitol concentration in serum was examined by an enzymatic fluorometric method. Rising antibody titers against C. albicans, mannan antigenemia, and an elevated D-arabinitol creatinine ratio were first observed between the 11th and 12th hospital days. Blood cultures obtained on 8th, 9th, and 11th hospital days grew C. albicans after 3 to 4 days of incubation. Of 11 serum samples, 5 were positive for mannan, whereas D-arabinitol creatinine ratio was positive in 7 of 9 samples. Blood cultures was the earliest evidence of Candida infections in our cases. However, because of saprophytic nature of Candida species, tests for antibodies, antigenemia, and the D-arabinitol creatinine ratio in combination with blood cultures are necessary to confirm systemic candidiasis at an early stage of infection.

Enzymatic fluorometric method for the determination of D-arabinitol in serum by initial rate analysis.

We describe a new, simple, fluorometric assay for D-arabinitol in serum. The method is based on oxidation of D-arabinitol by D-arabinitol dehydrogenase (EC 1.1.1.11), with the concomitant reduction of NAD. The initial rate of NAD reduction, which is proportional to the D-arabinitol content of serum, can be measured with a recording spectrofluorometer. Sensitivity, specificity, recovery and reproducibility experiments gave satisfactory results. The proposed method is suitable for clinical use, and may be helpful in the diagnosis of invasive candidiasis.

Enzymatic determination of D-mannose in serum.

A new and simple enzymatic assay for measuring D-mannose in serum is described. Endogenous glucose is eliminated from serum by use of glucose oxidase (EC 1.1.3.4) and catalase (EC 1.11.1.6). D-Mannose concentration is calculated from the increase in NADH formation after mannosephosphate isomerase (EC 5.3.1.8) is added. This increase is a result of coupling the following series of enzymes: hexokinase (EC 2.7.1.1), glucosephosphate isomerase (EC 5.3.1.9), and glucose-6-phosphate dehydrogenase (EC 1.1.1.49, NAD+-dependent). The study included subjects who were healthy volunteers and patients with suspected or proven fungal infections.

Pancreatic and salivary amylase determination using a short-chain chromogenic substrate (alpha-4-nitrophenyl-maltoheptaoside) and an amylase inhibitor.

We describe a simple method to determine serum amylase isoenzyme activity with alpha-4-nitrophenyl-maltoheptaoside as substrate and the use of an amylase inhibitor. Day-to-day reproducibility (CV) was 2% for total amylase, 3-5% for pancreatic and salivary amylase; within-day precision was 1% for total amylase, 1-4% for pancreatic and salivary amylase. The concentrations of total, pancreatic and salivary amylase were determined in 169 sera obtained from healthy adults (82 men and 87 women). Total, pancreatic and salivary amylase concentrations in males were respectively 184, 105 and 66; in females 210, 97 and 92 U/l (mean). Our method is simple and rapid; our results agree well with those of other authors, who have used electrophoretic or blue starch methods.

Sensitive fluorometric detection of heat-stable alkaline phosphatase from bloodstains for the forensic diagnosis of pregnancy.

Sensitive and simple procedures are established for the forensic pregnancy test from bloodstains. This paper describes new techniques based on heat stability of placental alkaline phosphatase. In this study the total and heat-stable alkaline phosphatase activities were determined using 4-methylumbelliferyl-phosphate as substrate. The ratio of heat-stable alkaline phosphatase to total alkaline phosphatase was calculated. A more simple screening test which was visible by exposure to UV light is described. These may be helpful in the diagnosis of pregnancy from only a slight bloodstain.

Muscular form of glycogenosis type II (Pompe's disease).

An 11-year-old boy who was previously thought to have progressive muscular dystrophy was studied clinically, biochemically, and histologically. He was seen initially with an amyotonic syndrome with no clinical evidence of heart disease. Light and histochemical examination showed vacuolar degeneration and abnormal accumulation of glycogen in the muscular fibers. Electron microscopy showed aggregates of glycogen granules surrounded by a well-defined membrane, as in previously reported cases of type II glycogenosis. Enzymatic study disclosed that acid alpha-glucosidase was deficient in muscle, liver, and heart tissue, although neutral alpha-glucosidase was present within normal ranges. Measurement of acid and neutral alpha-glucosidase activity in muscle from the patient and his sisters and in urine from them and their parents indicated that his sisters are heterozygotes and his parents probably are heterozygotes. The disease was transmitted as an autosomal-recessive trait.

Properties of the alpha-glucosidase from various human tissues in relation to glycogenosis type II (Pompe's disease).

The physico-chemical and electrophoretical properties of alpha-glucosidases from various human tissues and urine have been studied. There were some differences among Peak I enzymes (neutral alpha-glucosidases) obtained from liver, heart, muscle, kidney and urine. These differences are based on different effects of tris(hydroxymethyl)aminomethane and various thermostabilities of the Peak I enzymes. Electrophoretically, the Peak I enzyme activity at pH 6.5 from control tissues displayed a two-banded pattern except in kidney and urine. In the patient with the adult form of Pompe's disease the faster band of the Peak I enzyme from heart and muscle was not found and the slower band of the Peak I enzyme from liver was more cathodic. The results are discussed in relation to glycogenosis type II (Pompe's disease).

Urinary alpha-glucosidase analysis for the detection of the adult form of Pompe's disease.

Two alpha-glucosidases from human heart, liver, muscle, kidney and urine have been separated by means of Sephadex G-100 gel filtration. The first peak (Peak I) was neutral alpha-glucosidase and the second peak (Peak II) was lysosomal acid alpha-glucosidase. Peak II was absent in a patient with the adult form of Pompe's disease. KCl stimulated the activity of the Peak II enzyme but it strongly inhibited the activity of the Peak I enzyme measured at pH 4.0. Decreases in the urinary alpha-glucosidase activity measured at pH 4.0 with added KCl and the ratio of the activity at pH 4.0 with added KCl/the activity at pH 6.5 without KCl may aid in the detection of homozygotes or heterozygotes with the adult form of Pompe's disease.